Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Perioperative torsade de pointes: a systematic review of published case reports.

Johnston J, Pal S, Nagele P.

Anesth Analg. 2013 Sep;117(3):559-64. doi: 10.1213/ANE.0b013e318290c380. Epub 2013 Jun 6. Review.

2.

Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.

Vieweg WV, Hasnain M, Hancox JC, Baranchuk A, Digby GC, Kogut C, Crouse EL, Koneru JN, Deshmukh A, Pandurangi AK.

Psychopharmacology (Berl). 2013 Aug;228(4):515-24. doi: 10.1007/s00213-013-3192-8. Epub 2013 Jun 30. Review.

PMID:
23812796
3.

Haloperidol-induced torsade de pointes.

O'Brien JM, Rockwood RP, Suh KI.

Ann Pharmacother. 1999 Oct;33(10):1046-50.

PMID:
10534216
4.

Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.

Kao DP, Haigney MC, Mehler PS, Krantz MJ.

Addiction. 2015 Sep;110(9):1468-75. doi: 10.1111/add.13013.

5.

Postoperative QT interval prolongation in patients undergoing noncardiac surgery under general anesthesia.

Nagele P, Pal S, Brown F, Blood J, Miller JP, Johnston J.

Anesthesiology. 2012 Aug;117(2):321-8.

6.

[QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].

Lentini S, Rao ML, Schröder R, Lüderitz B, Bauriedel G.

Dtsch Med Wochenschr. 2001 Dec 7;126(49):1396-400. German.

PMID:
11740632
7.

Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.

Halkin A, Roth A, Lurie I, Fish R, Belhassen B, Viskin S.

J Am Coll Cardiol. 2001 Oct;38(4):1168-74.

8.

Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.

Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS.

Pharmacotherapy. 2003 Jun;23(6):802-5.

PMID:
12820821
9.

Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?

Vieweg WV, Hasnain M, Howland RH, Hettema JM, Kogut C, Wood MA, Pandurangi AK.

Am J Med. 2012 Sep;125(9):859-68. doi: 10.1016/j.amjmed.2011.12.002. Epub 2012 Jun 27. Review.

PMID:
22748401
10.

Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.

Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB.

Circulation. 1992 Nov;86(5):1376-82.

PMID:
1423949
11.

Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.

Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G.

Cardiovasc Res. 1993 Dec;27(12):2186-93.

PMID:
8313427
12.

Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation.

Gilmour RF Jr, Riccio ML, Locati EH, Maison-Blanche P, Coumel P, Schwartz PJ.

J Am Coll Cardiol. 1997 Jul;30(1):209-17.

13.

Citalopram, QTc Prolongation, and Torsades de Pointes.

Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, Knudsen A, May J.

Psychosomatics. 2015 Jan-Feb;56(1):36-43. doi: 10.1016/j.psym.2014.09.002. Epub 2014 Sep 6. Review.

PMID:
25619672
14.

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

Glassman AH, Bigger JT Jr.

Am J Psychiatry. 2001 Nov;158(11):1774-82. Review.

PMID:
11691681
15.

Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.

Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG.

Am Heart J. 2007 Jun;153(6):891-9. Review.

PMID:
17540188
16.

Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.

Hancox JC, Hasnain M, Vieweg WV, Crouse EL, Baranchuk A.

Ther Adv Infect Dis. 2013 Oct;1(5):155-65. doi: 10.1177/2049936113501816.

17.

QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Hasnain M, Vieweg WV.

CNS Drugs. 2014 Oct;28(10):887-920. doi: 10.1007/s40263-014-0196-9. Review.

PMID:
25168784
18.

Risk factors for QTc-prolongation: systematic review of the evidence.

Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V.

Int J Clin Pharm. 2017 Feb;39(1):16-25. doi: 10.1007/s11096-016-0414-2. Epub 2016 Dec 23. Review.

PMID:
28012118
19.

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.

Hohnloser SH, Klingenheben T, Singh BN.

Ann Intern Med. 1994 Oct 1;121(7):529-35. Review.

PMID:
8067651
20.

The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.

Topilski I, Rogowski O, Rosso R, Justo D, Copperman Y, Glikson M, Belhassen B, Hochenberg M, Viskin S.

J Am Coll Cardiol. 2007 Jan 23;49(3):320-8. Epub 2007 Jan 4.

Supplemental Content

Support Center